American biotechnology company at Waltham in Massachusetts, founded in 2018, which develops antibody drug conjugates. Its FateControl platform is designed to change how conjugates behave inside cells so that more of the payload reaches the tumour, with lead programmes against MET and other targets in lung and other solid tumours, and the company has raised venture funding to take them into clinical trials.
No hay comentarios disponibles.
Deja tu valoración & comentario